Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 inhibitors

C J Hawkey1

  • 1University of Nottingham, Queen's Medical Centre, UK.

Lancet (London, England)
|February 3, 1999
PubMed
Summary
This summary is machine-generated.

Aspirin and NSAIDs cause gastrointestinal issues by inhibiting cyclo-oxygenase (COX) enzymes. Selective COX-2 inhibitors offer potential for safer anti-inflammatory and pain relief without the damaging side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eradication of <i>Helicobacter pylori</i> for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: the HEAT RCT.

Health technology assessment (Winchester, England)·2025
Same author

Welcome to Frontline Gastroenterology.

Frontline gastroenterology·2017
Same author

What you need to know when you prescribe a proton pump inhibitor.

Frontline gastroenterology·2017
Same author

A drunk and disorderly country: a nationwide cross-sectional survey of alcohol use and misuse in Great Britain.

Frontline gastroenterology·2017
Same author

Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art Treatment.

Digestive diseases (Basel, Switzerland)·2017
Same author

Stem cells as treatment in inflammatory bowel disease.

Digestive diseases (Basel, Switzerland)·2013
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Inflammation Research

Background:

  • Aspirin has been used for over a century for pain relief and reducing inflammation.
  • Gastrointestinal toxicity of aspirin was recognized by 1938.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) developed since the 1960s have not provided a safer alternative to aspirin.

Purpose of the Study:

  • To investigate the potential for a
  • safer aspirin
  • by exploring selective cyclo-oxygenase-2 (COX-2) inhibition.
  • To determine if targeting COX-2 can separate therapeutic effects from gastrointestinal toxicity.

Main Methods:

  • Understanding the mechanism of action of aspirin and NSAIDs through prostaglandin synthesis inhibition.

Related Experiment Videos

  • Investigating the role of cyclo-oxygenase (COX) enzymes, specifically COX-1 and COX-2.
  • Evaluating the therapeutic potential of selective COX-2 inhibitors.

    • Main Results:

    • Inhibition of prostaglandin synthesis via COX enzymes is linked to both therapeutic benefits and toxic effects of NSAIDs.
    • Selective inhibition of the inducible COX-2 enzyme may break the link between efficacy and toxicity.
    • COX enzymes are key targets for anti-inflammatory drug development.

    Conclusions:

    • The development of selective COX-2 inhibitors offers a promising pathway towards achieving the long-sought
    • safer aspirin
    • .
    • Targeting COX-2 may provide effective anti-inflammatory and analgesic benefits with reduced gastrointestinal side effects.